DK2180882T3 - Farmaceutisk faststofsammensætning af matrix-type - Google Patents

Farmaceutisk faststofsammensætning af matrix-type

Info

Publication number
DK2180882T3
DK2180882T3 DK08838805.3T DK08838805T DK2180882T3 DK 2180882 T3 DK2180882 T3 DK 2180882T3 DK 08838805 T DK08838805 T DK 08838805T DK 2180882 T3 DK2180882 T3 DK 2180882T3
Authority
DK
Denmark
Prior art keywords
matrix
solid composition
pharmaceutical solid
type pharmaceutical
type
Prior art date
Application number
DK08838805.3T
Other languages
English (en)
Inventor
Kai Suzuki
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40567911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2180882(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of DK2180882T3 publication Critical patent/DK2180882T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK08838805.3T 2007-10-19 2008-09-26 Farmaceutisk faststofsammensætning af matrix-type DK2180882T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007272700 2007-10-19
PCT/JP2008/067996 WO2009051022A2 (en) 2007-10-19 2008-09-26 Matrix-type pharmaceutical solid preparation

Publications (1)

Publication Number Publication Date
DK2180882T3 true DK2180882T3 (da) 2013-05-27

Family

ID=40567911

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08838805.3T DK2180882T3 (da) 2007-10-19 2008-09-26 Farmaceutisk faststofsammensætning af matrix-type

Country Status (24)

Country Link
US (2) US9072670B2 (da)
EP (1) EP2180882B2 (da)
JP (1) JP4879351B2 (da)
KR (2) KR20150064227A (da)
CN (1) CN101854920B (da)
AR (1) AR068910A1 (da)
AU (1) AU2008313032B2 (da)
BR (1) BRPI0817822A2 (da)
CA (1) CA2702904A1 (da)
CY (1) CY1114051T1 (da)
DK (1) DK2180882T3 (da)
ES (1) ES2406939T3 (da)
HK (1) HK1144775A1 (da)
HR (1) HRP20130498T1 (da)
IL (1) IL204706A (da)
MX (1) MX2010004178A (da)
MY (1) MY147827A (da)
PL (1) PL2180882T3 (da)
PT (1) PT2180882E (da)
RU (2) RU2465916C2 (da)
SI (1) SI2180882T1 (da)
TW (1) TWI433679B (da)
WO (1) WO2009051022A2 (da)
ZA (1) ZA201002211B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8028771B2 (en) 2007-02-06 2011-10-04 Smith International, Inc. Polycrystalline diamond constructions having improved thermal stability
US7942219B2 (en) 2007-03-21 2011-05-17 Smith International, Inc. Polycrystalline diamond constructions having improved thermal stability
US9297211B2 (en) 2007-12-17 2016-03-29 Smith International, Inc. Polycrystalline diamond construction with controlled gradient metal content
AR071706A1 (es) * 2008-05-15 2010-07-07 Otsuka Pharma Co Ltd Una formulacion farmaceutica de cilostazol solida de liberacion sostenida y metodo de preparacion.
WO2010009430A2 (en) 2008-07-17 2010-01-21 Smith International, Inc. Methods of forming thermally stable polycrystalline diamond cutters
CN102020609A (zh) * 2009-09-17 2011-04-20 北京本草天源药物研究院 托伐普坦晶体或无定形物及其制备方法
CN102293734A (zh) * 2010-06-25 2011-12-28 江苏恒瑞医药股份有限公司 托伐普坦固体分散体及其制备方法
CN102552278A (zh) * 2010-12-23 2012-07-11 天津泰普药品科技发展有限公司 一种提高难溶性药物托伐普坦溶出度的药物组合物
CN102558051B (zh) * 2011-07-15 2016-08-10 天津泰普药品科技发展有限公司 一种托伐普坦晶体及其药物组合物
CN103007286B (zh) * 2011-09-28 2016-06-15 北京本草天源药物研究院 一种托伐普坦的固体药物组合物
TWI615157B (zh) * 2013-02-06 2018-02-21 大塚製藥股份有限公司 包括不定形西洛他唑的固體分散劑
TWI660748B (zh) 2013-03-01 2019-06-01 日商大塚製藥股份有限公司 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液
CN103880747B (zh) * 2014-03-20 2015-08-26 成都百裕科技制药有限公司 无定形托伐普坦的制备方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN106511351B (zh) * 2016-12-27 2020-04-03 吉林省博大伟业制药有限公司 聚普瑞锌在制备抗幽门螺旋杆菌药物中的应用
CN108478581A (zh) * 2018-05-09 2018-09-04 南通大学 防治运动病、梅尼埃病的药物及托伐普坦的医药用途
KR102138253B1 (ko) * 2018-08-17 2020-07-29 한국유나이티드제약 주식회사 실로스타졸 서방성 제제
WO2022150535A1 (en) * 2021-01-08 2022-07-14 Board Of Trustees Of Michigan State University Methods for forming cellulosic-based containers, related articles, and related compositions

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US202090A (en) * 1878-04-09 Improvement in plows
US3491070A (en) * 1966-11-25 1970-01-20 Goodrich Co B F 2 - ethylhexyl acrylate - n - octyl acrylamide - methacrylamide / acrylamide terpolymer
JPS6051106A (ja) 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤
US4968508A (en) † 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
JPH0443049A (ja) 1990-06-08 1992-02-13 Ricoh Co Ltd サーマルヘッドと厚膜金電極へのメッキ方法
SE9100284D0 (sv) 1991-01-30 1991-01-30 Astra Ab Novel peptide
JPH0624991A (ja) 1991-06-20 1994-02-01 Tokyo Tanabe Co Ltd ウルソデスオキシコール酸持続性製剤
JPH06199657A (ja) 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
JPH115739A (ja) 1997-06-17 1999-01-12 Taisho Yakuhin Kogyo Kk ベザフィブラート含有持続性製剤およびその製造方法
WO1999017742A2 (en) * 1997-10-03 1999-04-15 Elan Corporation, Plc Taste masked formulations
JP2002510336A (ja) 1998-04-11 2002-04-02 エレカッパ・ユウロテラピッチ・ソシエタ・ペル・アチオニ 水溶性ケトプロフェン塩を含有する薬学的調製物及びその使用方法
CN1272785A (zh) † 1998-06-11 2000-11-08 Em工业股份有限公司 微渗透药物控释系统
FR2781152B1 (fr) * 1998-07-20 2001-07-06 Permatec Tech Ag Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation
GT199900148A (es) 1998-09-10 2001-02-28 Desnaturalizantes para las sales aminas simpaticomimeticas.
IN191239B (da) † 1999-06-11 2003-10-11 Ranbaxy Lab Ltd
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
DE10046541A1 (de) * 2000-09-19 2002-03-28 Knoll Ag Mechanisch stabile darreichungsformen, enthaltend Ubichinone
US6884768B2 (en) * 2001-06-14 2005-04-26 Otsuka Pharmaceutical Co., Ltd. Medicinal compositions
KR100530546B1 (ko) 2001-07-27 2005-11-23 아스텔라스세이야쿠 가부시키가이샤 구강내에서 신속하게 붕괴되는 정제용 서방성 미립자가함유된 조성물 및 그의 제조 방법
CN1596101A (zh) † 2001-09-28 2005-03-16 麦克内尔-Ppc股份有限公司 含有糖果组分的剂型
AU2003206382B2 (en) 2002-01-03 2008-01-24 Smithkline Beecham Corporation Novel pharmaceutical dosage forms and method for producing same
EP1578350B1 (en) 2002-03-26 2009-05-27 Euro-Celtique S.A. Sustained-release gel coated compositions
US6946156B2 (en) † 2002-05-15 2005-09-20 Mcneil-Ppc, Inc. Process for enrobing a core
EP1572190B1 (en) * 2002-12-17 2007-04-18 Abbott GmbH & Co. KG Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
TWI357815B (en) 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
US20050147663A1 (en) 2003-07-17 2005-07-07 Mohan Mailatur S. Method of treatment for improved bioavailability
JP2005206490A (ja) 2004-01-21 2005-08-04 Pola Chem Ind Inc 経口投与用の組成物
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
US20050196355A1 (en) † 2004-03-03 2005-09-08 Constantine Georgiades Film products having controlled disintegration properties
US20050196447A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
GB2418854B (en) * 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
AU2005315855A1 (en) † 2004-12-17 2006-06-22 Boehringer Ingelheim International Gmbh Combination therapy comprising telmisartan and hydrochlorothiazide
US20060159753A1 (en) 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
MX2008000084A (es) * 2005-06-29 2008-03-18 Panacea Biotec Ltd Composiciones farmaceuticas de liberacion sostenida y procedimientos de las mismas.
EP1968553A2 (en) * 2005-11-09 2008-09-17 Novartis AG Process for making pharmaceutical compositions with a transient plasticizer
RU2443406C2 (ru) 2005-12-22 2012-02-27 Оцука Фармасьютикал Ко., Лтд. Способ получения содержащих лекарственное вещество восковых матричных частиц, экструдер для применения в способе и лекарственное средство с замедленным высвобождением, содержащее цилостазол
SG169334A1 (en) 2006-01-21 2011-03-30 Abbott Gmbh & Co Kg Dosage form and method for the delivery of drugs of abuse
CA2637274C (en) * 2006-01-24 2013-06-04 R-Tech Ueno, Ltd. Soft-gelatin capsule formulation

Also Published As

Publication number Publication date
TW200918079A (en) 2009-05-01
IL204706A (en) 2014-05-28
TWI433679B (zh) 2014-04-11
HRP20130498T1 (en) 2013-06-30
KR20100087011A (ko) 2010-08-02
EP2180882A2 (en) 2010-05-05
IL204706A0 (en) 2010-11-30
WO2009051022A3 (en) 2009-06-25
PT2180882E (pt) 2013-05-07
HK1144775A1 (en) 2011-03-11
KR20150064227A (ko) 2015-06-10
US20150150806A1 (en) 2015-06-04
JP4879351B2 (ja) 2012-02-22
BRPI0817822A2 (pt) 2015-03-31
JP2011500511A (ja) 2011-01-06
EP2180882B2 (en) 2017-06-28
KR101600099B1 (ko) 2016-03-04
AR068910A1 (es) 2009-12-16
US9289389B2 (en) 2016-03-22
ES2406939T3 (es) 2013-06-10
EP2180882B1 (en) 2013-03-27
CA2702904A1 (en) 2009-04-23
RU2012132627A (ru) 2014-02-10
SI2180882T1 (sl) 2013-05-31
RU2465916C2 (ru) 2012-11-10
WO2009051022A2 (en) 2009-04-23
RU2010119926A (ru) 2011-11-27
CY1114051T1 (el) 2016-07-27
US9072670B2 (en) 2015-07-07
AU2008313032B2 (en) 2013-05-02
AU2008313032A1 (en) 2009-04-23
MX2010004178A (es) 2010-05-03
RU2600797C2 (ru) 2016-10-27
US20100233265A1 (en) 2010-09-16
MY147827A (en) 2013-01-31
ZA201002211B (en) 2011-06-29
PL2180882T3 (pl) 2013-08-30
CN101854920B (zh) 2013-05-01
CN101854920A (zh) 2010-10-06

Similar Documents

Publication Publication Date Title
LTPA2018005I1 (lt) Farmacinė kompozicija
LTPA2018014I1 (lt) Farmacinė kompozicija 514
DK2180882T3 (da) Farmaceutisk faststofsammensætning af matrix-type
BRPI0721651A2 (pt) Composição farmacêutica
BRPI0715712A2 (pt) Composição farmacêutica
RU2493831C3 (ru) Фармацевтические композиции
BRPI0719393A2 (pt) Composição farmacêutica
DK1984009T3 (da) Farmaceutiske sammensætninger med forbedret stabilitet
DK2120884T3 (da) Farmaceutisk sammensætning
RU2398586C3 (ru) Фармацевтическая композиция
BRPI0813775A2 (pt) Composição
DK2041139T3 (da) Farmaceutiske forbindelser
BRPI0716325A2 (pt) Composição antimicrobianas
BRPI0810928A2 (pt) "composição farmacêutica"
FR2899479B1 (fr) Composition cicatrisante
ATE528048T1 (de) Schweisshemmende/desodorierende zusammensetzung
BRPI0716445A2 (pt) composiÇço farmacÊutica
BRPI0720234A2 (pt) Composição farmacêutica
BRPI0810557A2 (pt) composição
BRPI0811274A2 (pt) Composição
DK2285413T3 (da) Farmaceutisk sammensætning
DK2966175T3 (da) Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
BRPI0817833A2 (pt) Composição farmacêutica antimalárica
BRPI0820198A2 (pt) composições farmacêuticas
BRPI0921313A2 (pt) composição farmaucêutica